Parkinson disease in 2017

Changing views after 200 years of Parkinson disease

200 years after James Parkinson's An Essay on the Shaking Palsy, 2017 has seen important advances that are driving a shift towards a broader and more holistic understanding of Parkinson disease aetiology and progression. This shift might finally pave the way to entirely novel and more effective prevention and management strategies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Precision medicine in Parkinson disease.


  1. 1

    Obeso, J. A. et al. Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the Shaking Palsy. Mov. Disord. 32, 1264–1310 (2017).

    CAS  Article  Google Scholar 

  2. 2

    Espay, A. J. et al. Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials. Mov. Disord. 32, 319–324 (2017).

    Article  Google Scholar 

  3. 3

    Mass, E. et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature 549, 389–393 (2017).

    CAS  Article  Google Scholar 

  4. 4

    Witoelar, A. et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 74, 780–792 (2017).

    Article  Google Scholar 

  5. 5

    Pilotto, A. et al. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Mov. Disord. 32, 1025–1034 (2017).

    CAS  Article  Google Scholar 

  6. 6

    Fereshtehnejad, S.-M. et al. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain 140, 1959–1976 (2017).

    Article  Google Scholar 

  7. 7

    van Uem, J. et al. Health-related quality of life in patients with Parkinson's disease — a systematic review based on the ICF model. Neurosci. Biobehav. Rev. 61, 26–34 (2016).

    Article  Google Scholar 

  8. 8

    Henderson, E. J. et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. Neurol. 15, 249–258 (2016).

    CAS  Article  Google Scholar 

  9. 9

    Nieuwhof, F. et al. Impaired dual tasking in Parkinson's disease is associated with reduced focusing of cortico-striatal activity. Brain 140, 1384–1398 (2017).

    Article  Google Scholar 

  10. 10

    Mittal, S. et al. β2-adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science 357, 891–898 (2017).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Daniela Berg.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Maetzler, W., Berg, D. Changing views after 200 years of Parkinson disease. Nat Rev Neurol 14, 70–72 (2018).

Download citation

Further reading


Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing